Acorda Therapeutics Inc. [ACOR] Stock trading around $0.59 per share: What’s Next?

Acorda Therapeutics Inc. [NASDAQ: ACOR] stock went on an upward path that rose over 21.72% on Thursday, amounting to a one-week price increase of more than 11.53%. The company report on October 27, 2022 that Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


CEO video / Q&A with shareholders on October 28, 2022 to review business plan and ballot items for special meeting of stockholders.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a detailed, long-term business plan to drive shareholder value and also provided long-term financial guidance.

Over the last 12 months, ACOR stock dropped by -85.75%. The average equity rating for ACOR stock is currently 2.00, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $14.75 million, with 24.34 million shares outstanding and 24.17 million shares in the current float. Compared to the average trading volume of 2.89M shares, ACOR stock reached a trading volume of 14145205 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Acorda Therapeutics Inc. [ACOR]:

H.C. Wainwright have made an estimate for Acorda Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 17, 2021. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $31 to $6. The new note on the price target was released on August 14, 2019, representing the official price target for Acorda Therapeutics Inc. stock.

The Average True Range (ATR) for Acorda Therapeutics Inc. is set at 0.09, with the Price to Sales ratio for ACOR stock in the period of the last 12 months amounting to 0.12. The Price to Book ratio for the last quarter was 0.11.

ACOR Stock Performance Analysis:

Acorda Therapeutics Inc. [ACOR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.53. With this latest performance, ACOR shares gained by 102.68% in over the last four-week period, additionally sinking by -55.64% over the last 6 months – not to mention a drop of -85.75% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACOR stock in for the last two-week period is set at 57.99, with the RSI for the last a single of trading hit 58.45, and the three-weeks RSI is set at 57.16 for Acorda Therapeutics Inc. [ACOR]. The present Moving Average for the last 50 days of trading for this stock 0.4117, while it was recorded at 0.5320 for the last single week of trading, and 0.9812 for the last 200 days.

Insight into Acorda Therapeutics Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Acorda Therapeutics Inc. [ACOR] shares currently have an operating margin of -55.24 and a Gross Margin at +44.56. Acorda Therapeutics Inc.’s Net Margin is presently recorded at -80.54.

Return on Equity for this stock declined to -53.43, with Return on Assets sitting at -16.54.

Acorda Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.50 and a Current Ratio set at 1.90.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ACOR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Acorda Therapeutics Inc. go to 46.00%.

Acorda Therapeutics Inc. [ACOR] Insider Position Details

There are presently around $4 million, or 27.40% of ACOR stock, in the hands of institutional investors. The top three institutional holders of ACOR stocks are: DAVIDSON KEMPNER CAPITAL MANAGEMENT LP with ownership of 2,395,668, which is approximately New of the company’s market cap and around 0.10% of the total institutional ownership; CANYON CAPITAL ADVISORS LLC, holding 1,193,988 shares of the stock with an approximate value of $0.7 million in ACOR stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $0.53 million in ACOR stock with ownership of nearly 27.446% of the company’s market capitalization.

20 institutional holders increased their position in Acorda Therapeutics Inc. [NASDAQ:ACOR] by around 4,153,851 shares. Additionally, 13 investors decreased positions by around 852,450 shares, while 10 investors held positions by with 1,665,314 shares. The mentioned changes placed institutional holdings at 6,671,615 shares, according to the latest SEC report filing. ACOR stock had 9 new institutional investments in for a total of 2,755,229 shares, while 7 institutional investors sold positions of 499,993 shares during the same period.


Please enter your comment!
Please enter your name here